Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 mars 2009 16h30 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences Receives NASDAQ Notice; Will Request Hearing

SOUTH SAN FRANCISCO, Calif., March 11, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB) today announced that the Company received a letter on March 5, 2009 from the Listing Qualifications Staff...
02 févr. 2009 07h30 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences to Present at the 11th Annual BIO CEO & Investor Conference On February 10, 2009

SOUTH SAN FRANCISCO, Calif., Feb. 2, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
13 janv. 2009 07h30 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences Phase 1 Data On Menadione, Its Novel First-in-Class Compound for Treatment-Limiting Skin Toxicity Associated With EGFR Inhibitors, to be Presented At 33rd Hawaii Dermatology Seminar

SOUTH SAN FRANCISCO, Calif., Jan. 13, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced an...
12 janv. 2009 07h30 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences Appoints Thomas J. Tarlow as Vice President, Regulatory Affairs and Quality

SOUTH SAN FRANCISCO, Calif., Jan. 12, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
08 déc. 2008 07h30 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences Completes Phase 1 Clinical Trial of Menadione, Its Novel First-in-class Compound for Treatment-Limiting Skin Toxicity Associated With EGFR Inhibitors

SOUTH SAN FRANCISCO, Calif., Dec. 8, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced the...
01 déc. 2008 07h30 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences to Present Data On Marqibo, Its Lead Novel Anti-Cancer Compound, At 2008 American Society of Hematology (ASH) Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 1, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
21 nov. 2008 16h47 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences Receives NASDAQ Notification

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, reported that it...
20 nov. 2008 07h30 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences to Present At the 20th Annual Piper Jaffray Health Care Conference On December 3, 2008

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that...
13 nov. 2008 16h00 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences Reports Third Quarter 2008 Results

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced its...
06 nov. 2008 07h30 HE | Source: Talon Therapeutics, Inc.

Hana Biosciences to Report Third Quarter 2008 Results and Business Update On November 13, 2008

SOUTH SAN FRANCISCO, Calif., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, will announce its...

Page précédente

Page suivante